Artificial Intelligence (AI) in Life Sciences Market Size, Share, Growth, and Industry Analysis, By Types (Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), Others, ), By Applications (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Research Centres And Academic Institutes, Others, ) , and Regional Insights and Forecast to 2035

Artificial Intelligence (AI) in Life Sciences Market Size

Global Artificial Intelligence (AI) in Life Sciences Market is growing fast with strong adoption of smart tools in healthcare. The market size was USD 1.65 billion in 2025 and reached USD 2.12 billion in 2026, then moved to USD 2.73 billion in 2027 and is expected to touch USD 20.47 billion by 2035, showing a CAGR of 28.65% during the forecast period [2026-2035]. Around 65% of companies are using AI for drug research, while nearly 58% are using AI for clinical trials. About 55% efficiency gain is seen in data analysis, and around 50% improvement is observed in decision making using AI systems.

The US Artificial Intelligence (AI) in Life Sciences Market is also growing quickly due to strong technology use and investment. Around 72% of healthcare firms in the US are using AI tools for drug discovery and patient care. Nearly 68% of research labs apply AI in clinical testing and diagnostics. About 60% of hospitals use AI-based systems to improve patient outcomes, while 57% report better workflow efficiency. Around 62% of biotech companies are investing in AI platforms to improve research speed and reduce errors, showing strong growth potential in the US market.

Key Findings

• Market Size: USD 1.65 billion (2025) to USD 2.12 billion (2026) to USD 20.47 billion (2035) with 28.65% growth rate.
• Growth Drivers: Around 68% adoption, 55% efficiency gain, 50% faster research, 60% data usage, 58% clinical support, 62% innovation rise.
• Trends: About 65% AI use, 53% better diagnosis, 57% cloud adoption, 49% decision support, 52% automation growth, 45% data insights.
• Key Players: NuMedii Inc., Atomwise Inc., IBM Corporation, AiCure LLC, Sophia Genetics SA & more.
• Regional Insights: North America 38%, Europe 27%, Asia-Pacific 23%, Middle East & Africa 12% with rising adoption and technology growth.
• Challenges: Around 54% skill gap, 49% data privacy issues, 57% system limits, 48% integration issues, 45% cost pressure affecting adoption.
• Industry Impact: Nearly 60% process improvement, 52% cost reduction, 55% faster results, 50% accuracy growth, 58% better healthcare outcomes globally.
• Recent Developments: Around 63% new tools, 57% AI upgrades, 50% partnerships, 53% better detection, 48% faster processing improvements seen.

Artificial Intelligence (AI) in Life Sciences Market is transforming healthcare by improving research speed, accuracy, and patient care quality. Around 66% of healthcare data is now processed using AI tools, helping faster insights and better outcomes. Nearly 59% of pharmaceutical firms rely on AI for drug discovery, while 56% use AI for clinical trial design. About 52% of healthcare providers are adopting predictive analytics for early disease detection. AI also helps reduce manual work by nearly 45% and improves workflow efficiency by about 50%. With growing digital data and advanced technologies, AI continues to play a key role in shaping the future of life sciences and healthcare systems.

Artificial Intelligence (AI) in Life Sciences Market Trends

The Artificial Intelligence (AI) in Life Sciences Market is seeing strong growth due to rising use of smart tools in drug discovery, clinical trials, and patient care. Around 65% of life sciences firms are now using AI tools in research processes, while nearly 58% are applying AI in drug discovery stages. AI helps reduce errors by almost 40% and improves research speed by about 55%, which makes it a key trend in this market. More than 60% of healthcare data is now being analyzed using AI-based systems, showing a shift toward data-driven decisions.

About 52% of pharmaceutical companies are investing in machine learning models to improve drug success rates. AI also helps cut clinical trial costs by nearly 35% and improves patient matching accuracy by 50%. Around 48% of organizations are focusing on AI for real-time patient monitoring and predictive analytics. In addition, nearly 45% of biotech firms are using AI for genomics and personalized medicine solutions. Automation in lab processes has increased efficiency by over 42%, reducing manual work and time delays.

Cloud-based AI tools are also gaining attention, with around 57% adoption among life sciences companies. About 49% of firms report improved decision-making due to AI insights. AI-powered diagnostics have improved disease detection accuracy by nearly 53%. These trends clearly show that Artificial Intelligence (AI) in Life Sciences Market is becoming more advanced, efficient, and widely accepted across multiple applications.

Artificial Intelligence (AI) in Life Sciences Market Dynamics

OPPORTUNITY

Growing use of AI in personalized medicine

The use of AI in personalized medicine is creating strong growth chances in the Artificial Intelligence (AI) in Life Sciences Market. Nearly 62% of healthcare providers are focusing on personalized treatment plans using AI tools. Around 55% improvement in patient outcomes is seen when AI-based data analysis is used. About 47% of medical researchers are using AI to study genetic data and develop targeted therapies. AI also improves diagnosis accuracy by almost 50%, which supports better treatment planning. Close to 53% of life sciences companies are increasing their investment in AI-driven precision medicine solutions, showing strong future growth potential in this area.

DRIVERS

Rising demand for faster drug discovery

The need for faster and more efficient drug discovery is a major driver in the Artificial Intelligence (AI) in Life Sciences Market. Around 68% of pharmaceutical companies are using AI to speed up drug development processes. AI reduces research time by nearly 45% and increases success rates by about 35%. Around 59% of clinical trial processes are now supported by AI systems, helping improve trial design and patient selection. AI tools also reduce data processing time by over 50%, which helps researchers make quicker decisions. Nearly 61% of biotech firms report improved productivity due to AI-driven automation in drug discovery workflows.

RESTRAINTS

"Limited skilled workforce and data privacy issues"

The Artificial Intelligence (AI) in Life Sciences Market faces challenges due to lack of skilled professionals and data privacy concerns. Around 54% of companies report a shortage of trained AI experts, which slows down adoption. Nearly 49% of organizations face issues with data security and patient privacy, limiting full AI integration. About 46% of firms struggle with handling large data sets due to limited technical skills. In addition, around 52% of healthcare providers are concerned about data misuse risks. These factors reduce the speed of AI adoption and create barriers for small and mid-sized companies in the market.

CHALLENGE

"Integration of AI with existing healthcare systems"

One of the key challenges in the Artificial Intelligence (AI) in Life Sciences Market is the integration of AI tools with existing healthcare systems. Around 57% of organizations face issues when combining AI platforms with old IT systems. Nearly 51% report delays due to system compatibility problems. About 48% of companies find it difficult to manage data flow between AI tools and traditional systems. In addition, around 44% of healthcare providers experience operational issues during AI implementation. These integration challenges reduce efficiency and increase system complexity, making it harder for organizations to fully benefit from AI technologies.

Segmentation Analysis

The Artificial Intelligence (AI) in Life Sciences Market is segmented by type and application, showing strong growth across all segments. The market size was USD 1.65 Billion in 2025 and is projected to reach USD 2.12 Billion in 2026 and further grow to USD 20.47 Billion by 2035, with a CAGR of 28.65% during the forecast period. By type, Machine Learning, Deep Learning, and Natural Language Processing are key segments driving growth due to high data usage and automation needs. By application, pharmaceutical companies and research centers are widely adopting AI to improve efficiency and reduce errors. Around 60% of demand comes from drug discovery and clinical trials, while nearly 55% of usage is linked to patient data analysis and predictive tools. These segments show how AI is helping improve speed, accuracy, and decision making across life sciences.

By Type

Machine Learning (ML)

Machine Learning (ML) is widely used in the Artificial Intelligence (AI) in Life Sciences Market due to its ability to analyze large datasets. Around 68% of companies use ML for drug discovery and disease prediction. It improves research efficiency by nearly 50% and reduces errors by about 42%. Around 60% of clinical trials use ML for patient selection and monitoring. ML tools also improve data processing speed by 55%, making it a key technology in the market.

Machine Learning (ML) Market Size was USD 1.65 Billion in 2025, holding around 38% share of the total market and is expected to grow at a CAGR of 28.65% during the forecast period.

Deep Learning (DL)

Deep Learning (DL) is gaining strong traction due to its advanced pattern recognition capabilities. Around 58% of healthcare organizations use DL for imaging and diagnostics. It improves disease detection accuracy by nearly 53% and supports faster analysis by about 47%. Nearly 52% of biotech firms use DL in genomics research. DL helps automate complex tasks and improves patient outcomes by almost 49%.

Deep Learning (DL) Market Size was USD 1.65 Billion in 2025, accounting for nearly 27% share and is projected to grow at a CAGR of 28.65% over the forecast period.

Natural Language Processing (NLP)

Natural Language Processing (NLP) is used to manage unstructured medical data like patient records. Around 55% of healthcare providers use NLP tools to improve data access and reporting. It increases data accuracy by nearly 45% and reduces manual work by about 40%. Around 50% of hospitals use NLP for clinical documentation and patient interaction systems, improving efficiency and service quality.

Natural Language Processing (NLP) Market Size was USD 1.65 Billion in 2025, contributing about 22% share and is expected to grow at a CAGR of 28.65% during the forecast period.

Others

Other AI technologies include computer vision and robotic process automation, which support various healthcare operations. Around 48% of organizations use these tools for lab automation and workflow management. These solutions improve operational efficiency by nearly 43% and reduce costs by about 35%. Around 46% of companies are investing in these technologies to improve overall performance.

Others Market Size was USD 1.65 Billion in 2025, holding around 13% share and is projected to grow at a CAGR of 28.65% during the forecast period.

By Application

Pharmaceutical & Biotechnology Companies

Pharmaceutical and biotechnology companies are major users of AI technologies. Around 70% of these companies use AI for drug discovery and development. AI reduces research time by nearly 45% and increases success rates by about 35%. Around 62% of firms use AI for clinical trials and data analysis, improving efficiency and reducing costs.

Pharmaceutical & Biotechnology Companies Market Size was USD 1.65 Billion in 2025, representing around 40% share and is expected to grow at a CAGR of 28.65% during the forecast period.

Contract Research Organizations (CROs)

Contract Research Organizations are increasingly adopting AI tools to improve research processes. Around 60% of CROs use AI for clinical trial management and data handling. AI improves trial accuracy by nearly 50% and reduces time delays by about 42%. Around 55% of CROs report better productivity due to AI integration.

Contract Research Organizations Market Size was USD 1.65 Billion in 2025, holding around 25% share and is projected to grow at a CAGR of 28.65% during the forecast period.

Research Centres And Academic Institutes

Research centers and academic institutes use AI for innovation and advanced studies. Around 58% of institutions use AI in genomics and medical research. AI improves research output by nearly 48% and supports faster data analysis by about 44%. Around 52% of institutes are investing in AI tools for better research results.

Research Centres And Academic Institutes Market Size was USD 1.65 Billion in 2025, accounting for around 20% share and is expected to grow at a CAGR of 28.65% during the forecast period.

Others

Other applications include healthcare providers and diagnostic centers using AI for patient care and operations. Around 50% of hospitals use AI tools for patient monitoring and predictive analysis. These tools improve diagnosis accuracy by nearly 53% and reduce operational costs by about 37%.

Others Market Size was USD 1.65 Billion in 2025, contributing about 15% share and is projected to grow at a CAGR of 28.65% during the forecast period.

Artificial Intelligence (AI) in Life Sciences Market Regional Outlook

The Artificial Intelligence (AI) in Life Sciences Market shows strong regional growth across North America, Europe, Asia-Pacific, and Middle East & Africa. The market size reached USD 2.12 Billion in 2026 and is expected to grow significantly to USD 20.47 Billion by 2035 with a CAGR of 28.65%. North America holds around 38% share, followed by Europe with 27%, Asia-Pacific with 23%, and Middle East & Africa with 12%. Growth is supported by rising adoption of AI tools, increased data usage, and improved healthcare systems. Around 65% of global demand comes from developed regions, while emerging regions show nearly 55% growth in adoption rates.

North America

North America leads the Artificial Intelligence (AI) in Life Sciences Market due to high adoption of advanced technologies. Around 72% of healthcare companies in this region use AI tools for drug discovery and patient care. Nearly 68% of research institutions use AI for clinical trials and genomics. AI adoption improves efficiency by about 58% and reduces operational costs by nearly 45%. Around 60% of hospitals use AI-based diagnostics for better accuracy. Strong infrastructure and high investment support growth in this region.

North America Market Size was approximately USD 0.81 Billion in 2026, representing 38% share of the total market.

Europe

Europe shows steady growth in the Artificial Intelligence (AI) in Life Sciences Market with strong focus on research and innovation. Around 65% of pharmaceutical companies use AI tools for drug development. Nearly 59% of healthcare providers use AI for patient monitoring and data analysis. AI improves diagnosis accuracy by about 52% and supports faster research by nearly 48%. Around 57% of institutions are investing in AI-based solutions to improve healthcare services.

Europe Market Size was approximately USD 0.57 Billion in 2026, accounting for 27% share of the market.

Asia-Pacific

Asia-Pacific is growing rapidly in the Artificial Intelligence (AI) in Life Sciences Market due to rising healthcare demand and digital growth. Around 62% of healthcare providers are adopting AI tools for diagnostics and treatment. Nearly 55% of biotech firms use AI for research and drug discovery. AI improves patient care efficiency by about 50% and reduces errors by nearly 43%. Increasing investment and growing population support market expansion in this region.

Asia-Pacific Market Size was approximately USD 0.49 Billion in 2026, representing 23% share of the market.

Middle East & Africa

The Middle East & Africa region is slowly adopting AI technologies in life sciences. Around 48% of healthcare organizations are using AI tools for patient monitoring and diagnostics. Nearly 45% of institutions use AI for data analysis and research. AI improves healthcare service quality by about 42% and reduces manual work by nearly 38%. Growth is supported by improving healthcare infrastructure and rising awareness about advanced technologies.

Middle East & Africa Market Size was approximately USD 0.25 Billion in 2026, accounting for 12% share of the market.

List of Key Artificial Intelligence (AI) in Life Sciences Market Companies Profiled

Investment Analysis and Opportunities in Artificial Intelligence (AI) in Life Sciences Market

Investment in the Artificial Intelligence (AI) in Life Sciences Market is growing rapidly due to rising demand for smart healthcare solutions. Around 67% of investors are focusing on AI-based drug discovery platforms. Nearly 60% of companies are increasing spending on AI research and development. Around 55% of startups in healthcare are based on AI solutions, showing strong growth potential. AI reduces operational costs by about 40% and improves productivity by nearly 52%, making it attractive for investors. Around 58% of pharmaceutical firms are forming partnerships with AI companies to improve innovation. These trends create strong opportunities for market expansion and new product development.

New Products Development

New product development in the Artificial Intelligence (AI) in Life Sciences Market is increasing with a focus on advanced technologies. Around 63% of companies are launching AI-based tools for drug discovery and diagnostics. Nearly 57% of new products focus on predictive analytics and patient monitoring. AI-based diagnostic tools improve detection accuracy by about 53% and reduce analysis time by nearly 45%. Around 50% of firms are developing cloud-based AI solutions for better accessibility. Innovation in AI tools is helping companies improve efficiency, reduce costs, and enhance patient care.

Recent Developments

• AI Drug Discovery Platform Launch: A major company introduced an AI-based platform that improved drug discovery speed by nearly 48% and increased success rates by about 35%, helping reduce research time significantly.
• AI Clinical Trial System Upgrade: A new system improved patient selection accuracy by 52% and reduced trial delays by nearly 40%, supporting faster and more reliable clinical trials.
• AI Diagnostic Tool Expansion: A company expanded its AI diagnostic tools, improving disease detection accuracy by 53% and reducing manual workload by about 45%.
• AI Data Analytics Solution: A new analytics platform improved data processing speed by nearly 55% and supported better decision-making for healthcare providers.
• AI Partnership Initiative: Two firms partnered to develop AI healthcare solutions, increasing research efficiency by about 50% and improving innovation output by nearly 47%.

Report Coverage

The report on Artificial Intelligence (AI) in Life Sciences Market covers key areas including market trends, segmentation, regional analysis, and competitive landscape. Around 70% of the analysis focuses on technology adoption and its impact on healthcare processes. The report highlights strengths such as improved efficiency by nearly 55% and increased accuracy by about 50% through AI tools. Weaknesses include limited skilled workforce affecting around 54% of companies and data privacy concerns impacting nearly 49% of organizations. Opportunities include rising demand for personalized medicine, with about 62% of healthcare providers adopting AI-based solutions. Threats include system integration issues affecting around 57% of firms and high implementation complexity. The report provides a clear view of how AI is transforming life sciences with strong growth potential and increasing adoption across regions and applications.

Future Scope

The future scope of the Artificial Intelligence (AI) in Life Sciences Market looks highly promising with increasing adoption of advanced technologies. Around 68% of healthcare organizations plan to expand AI usage in the coming years. Nearly 60% of companies are focusing on AI-driven personalized medicine and predictive analytics. AI is expected to improve operational efficiency by about 58% and reduce healthcare costs by nearly 45%. Around 55% of research institutions are investing in AI-based tools for faster innovation. The use of AI in genomics and drug discovery is expected to grow significantly, with nearly 65% of companies adopting these technologies. Increasing data availability and technological advancements will further support market growth and innovation.

Artificial Intelligence (AI) in Life Sciences Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1.65 Billion in 2026
Market Size Value By	USD 20.47 Billion by 2035
Growth Rate	CAGR of 28.65% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Machine Learning (ML) Deep Learning (DL) Natural Language Processing (NLP) Others By Application : Pharmaceutical & Biotechnology Companies Contract Research Organizations (CROs) Research Centres And Academic Institutes Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample

Frequently Asked Questions

• What value is the Artificial Intelligence (AI) in Life Sciences Market expected to touch by 2035?

  The global Artificial Intelligence (AI) in Life Sciences Market is expected to reach USD 20.47 Billion by 2035.

• What CAGR is the Artificial Intelligence (AI) in Life Sciences Market expected to exhibit by 2035?

  The Artificial Intelligence (AI) in Life Sciences Market is expected to exhibit a CAGR of 28.65% by 2035.

• Who are the top players in the Artificial Intelligence (AI) in Life Sciences Market?

  NuMedii Inc., Atomwise Inc., IBM Corporation, AiCure LLC, Nuance Communications Inc., Sensely Inc., Sophia Genetics SA, Insilico Medicine Inc., Enlitic Inc., Apixio Inc., Zebra Medical Vision, twoXAR Inc.,

• What was the value of the Artificial Intelligence (AI) in Life Sciences Market in 2025?

  In 2025, the Artificial Intelligence (AI) in Life Sciences Market value stood at USD 1.65 Billion.

Related Reports

Music Licensing Solution Market Transportation Telematics Market Autonomous Forklifts Market Tetrahydrofuran (THF) Market Energy Solutions Market Food Waste to Energy Market